Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review
PURPOSEBlockage of PD-1 with drugs such as nivolumab (Nivo) and pembrolizumab (Pembro) has been successfully implemented in the treatment of Hodgkin lymphoma among other types of tumors. Exorbitant costs hinder access for many patients living in low- and middle-income countries (LMICs). Dose reducti...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Clinical Oncology
2025-05-01
|
| Col·lecció: | JCO Global Oncology |
| Accés en línia: | https://ascopubs.org/doi/10.1200/GO-24-00538 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|